Core Insights - The strategic collaboration between Maiwei Biopharma and DeepMind Technology aims to transform biopharmaceutical research from a traditional experimental-driven model to a computational-driven model, addressing long-standing issues of lengthy R&D cycles, high costs, and low efficiency [1][3] Group 1: Company Overview - Maiwei Biopharma is an innovative biopharmaceutical company with a full industry chain layout, committed to turning innovation into reality and meeting unmet clinical needs globally through source innovation [1][2] - DeepMind Technology is a leader in AI for Science, utilizing AI to learn scientific principles and solve key problems in scientific research and industrial development [1][2] Group 2: Collaboration Details - The partnership will leverage both companies' strengths in biopharmaceutical R&D and AI large models to create a biopharmaceutical R&D large model platform, establishing a new paradigm for innovative drug development [1][3] - Two main areas of collaboration include: - Knowledge Engine Construction: Utilizing the Uni-SMART multimodal scientific literature model to build a knowledge engine for biopharmaceutical innovation, enhancing research efficiency and accelerating the R&D process [2] - Innovative Target Exploration: Combining Maiwei's ADC technology with DeepMind's RiDYMO platform to explore challenging drug targets and improve molecular discovery processes [2]